Search

Your search keyword '"Carson, Kenneth R."' showing total 595 results
Start Over Author "Carson, Kenneth R."
595 results on '"Carson, Kenneth R."'

104. Abstract LB-326: Identification of novel recurrent mutations in follicular lymphoma

Author

Krysiak, Kilannin, primary, Gomez, Felicia, additional, White, Brian S., additional, Matlock, Matthew, additional, Miller, Chris A., additional, Fulton, Robert S., additional, Kreisel, Friederike, additional, Cashen, Amanda F., additional, Carson, Kenneth R., additional, Berrien-Elliott, Melissa M., additional, Bartlett, Nancy L., additional, Wilson, Richard K., additional, Mardis, Elaine R., additional, Griffith, Malachi, additional, Griffith, Obi L., additional, and Fehniger, Todd A., additional

Published
2016
Full Text
View/download PDF

105. Longitudinal Body Composition Changes in Diffuse Large B-cell Lymphoma Survivors: A Retrospective Cohort Study of United States Veterans

Author

Xiao, Daphne Y., primary, Luo, Suhong, additional, O’Brian, Katiuscia, additional, Sanfilippo, Kristen M., additional, Ganti, Arun, additional, Riedell, Peter, additional, Lynch, Ryan C., additional, Liu, Weijian, additional, Kahl, Brad S., additional, Cashen, Amanda F., additional, Fehniger, Todd A., additional, and Carson, Kenneth R., additional

Published
2016
Full Text
View/download PDF

106. Identifying existing Choosing Wisely recommendations of high relevance and importance to hematology

Author

Hicks, Lisa K., primary, Rajasekhar, Anita, additional, Bering, Harriet, additional, Carson, Kenneth R., additional, Kleinerman, Judith, additional, Kukreti, Vishal, additional, Ma, Alice, additional, Mueller, Brigitta U., additional, O'Brien, Sarah H., additional, Panepinto, Julie A., additional, Pasquini, Marcelo C., additional, Sarode, Ravi, additional, and Wood, William A., additional

Published
2016
Full Text
View/download PDF

109. Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project

Author

Carson, Kenneth R., Newsome, Scott D., Kim, Ellen J., Wagner-Johnston, Nina D., von Geldern, Gloria, Moskowitz, Craig H., Moskowitz, Alison J., Rook, Alain H., Jalan, Pankaj, Loren, Alison W., Landsburg, Daniel, Coyne, Thomas, Tsai, Donald, Raisch, Dennis W., Norris, LeAnn B., Bookstaver, P Brandon, Sartor, Oliver, and Bennett, Charles L.

Subjects
Adult, Brentuximab Vedotin, Immunoconjugates, Lymphoma, Primary Cutaneous Anaplastic Large Cell, Mycosis Fungoides, Leukoencephalopathy, Progressive Multifocal, Humans, Middle Aged, Hodgkin Disease, Article, Aged
Abstract

Brentuximab vedotin (BV) is an anti-CD30 monoclonal antibody-drug conjugate that was approved in 2011 for the treatment of patients with anaplastic large cell and Hodgkin lymphomas. The product label indicates that 3 patients who were treated with BV developed progressive multifocal leukoencephalopathy (PML), a frequently fatal JC virus-induced central nervous system infection. Prior immunosuppressive therapy and compromised immune systems were postulated risk factors. In the current study, the authors reported 5 patients who developed BV-associated PML, including 2 immunocompetent patients.Case information was obtained from clinicians (4 patients) or a US Food and Drug Administration database (1 patient).All 5 patients had lymphoid malignancies. Two patients with cutaneous T-cell lymphomas had not previously received chemotherapy. PML developed after a median of 3 BV doses (range, 2 doses-6 doses) and within a median of 7 weeks after BV initiation (range, 3 weeks-34 weeks). Presenting findings included aphasia, dysarthria, confusion, hemiparesis, and gait dysfunction; JC virus in the cerebrospinal fluid (2 patients) or central nervous system biopsy (3 patients); and brain magnetic resonance imaging scans with white matter abnormalities (5 patients). Four patients died at a median of 8 weeks (range, 6 weeks-16 weeks) after PML diagnosis. The sole survivor developed immune reconstitution inflammatory syndrome.PML can develop after a few BV doses and within weeks of BV initiation. Clinicians should be aware of this syndrome, particularly when neurologic changes develop after the initiation of BV treatment. The decision to administer BV to patients with indolent cutaneous lymphomas should be based on consideration of risk-benefit profiles and of alternative options.

Published
2013

110. Obesity and Reproductive Function

Author

Jungheim, Emily S., Travieso, Jennifer L., Carson, Kenneth R., and Moley, Kelle H.

Abstract

Obesity is associated with multiple adverse reproductive outcomes, but the mechanisms involved are largely unknown. Public health scientists studying obesity and its effects on health outcomes have referred to obesity as a “complex system”, defined as a system of heterogeneous parts interacting in non-linear ways to influence the behavior of the parts as a whole1,2. By this definition, human reproduction is also a complex system which may explain some of the difficulty in identifying the mechanisms linking obesity and adverse reproductive function. Despite the difficulties, research on obesity and reproduction is important as there is an epidemic of obesity among reproductive age women with associated consequences for future generations. In this review we discuss the adverse reproductive outcomes associated with obesity and data from translational studies of the mechanisms involved. We conclude with a brief discussion of public health policy as it relates to the treatment of infertility in obese women.

Published
2024
Full Text
View/download PDF

115. Recurrent Somatic Genomic Alterations in Follicular NHL (FL) Revealed By Exome and Custom-Capture Next Generation Sequencing

Author

Fehniger, Todd A, primary, Krysiak, Kilannin, additional, White, Brian S, additional, Matlock, Matthew, additional, Miller, Chris, additional, Fulton, Robert, additional, Kreisel, Friederike, additional, Fronick, Catrina, additional, Cook, Lisa, additional, Veizer, Joelle, additional, Cashen, Amanda F., additional, Carson, Kenneth R, additional, Berrien-Elliott, Melissa M, additional, Bartlett, Nancy L, additional, Wilson, Richard K, additional, Mardis, Elaine R, additional, Ley, Timothy J, additional, Griffith, Malachi, additional, and Griffith, Obi L, additional

Published
2015
Full Text
View/download PDF

116. A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial

Author

Advani, Ranjana H., primary, Ansell, Stephen M., additional, Lechowicz, Mary J., additional, Beaven, Anne W., additional, Loberiza, Fausto, additional, Carson, Kenneth R., additional, Evens, Andrew M., additional, Foss, Francine, additional, Horwitz, Steven, additional, Pro, Barbara, additional, Pinter-Brown, Lauren C., additional, Smith, Sonali M., additional, Shustov, Andrei R., additional, Savage, Kerry J., additional, and M. Vose, Julie, additional

Published
2015
Full Text
View/download PDF

118. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update

Author

Smith, Thomas J., primary, Bohlke, Kari, additional, Lyman, Gary H., additional, Carson, Kenneth R., additional, Crawford, Jeffrey, additional, Cross, Scott J., additional, Goldberg, John M., additional, Khatcheressian, James L., additional, Leighl, Natasha B., additional, Perkins, Cheryl L., additional, Somlo, George, additional, Wade, James L., additional, Wozniak, Antoinette J., additional, and Armitage, James O., additional

Published
2015
Full Text
View/download PDF

125. Clinical Outcomes of Patients with Anaplastic Large Cell Lymphoma, Anaplastic Lymphoma Kinase-Positive (ALCL, ALK+): Data from 119 Patients Prospectively Registered in the International T-Cell Project

Author

Shustov, Andrei, Bellei, Monica, Pileri, Stefano A., Montoto, Silvia, Manni, Martina, Horwitz, Steven M., Cabrera, Maria Elena, Chiattone, Carlos, Nagler, Arnon, González de Villambrosia, Sonia, Perez Saenz, Maria Angeles, Merli, Francesco, Ferreri, Andrés J M, Prates, Maria Virginia, Carson, Kenneth R., Re, Alessandro, Rigacci, Luigi, Nassi, Luca, Zilioli, Vittorio Ruggero, and Federico, Massimo

Published
2017
Full Text
View/download PDF

128. The Role of Upfront Hematopoietic Stem Cell Transplantation (HSCT) in Peripheral T-Cell Lymphoma (PTCL) Patients in Complete Remission (CR) with a Special Focus on Nodal PTCL: Report from the Comprehensive Oncology Measures for Peripheral T-Cell Lymphoma Treatment (COMPLETE), a Prospective Multicenter Cohort Study

Author

Park, Steven I, Horwitz, Steven M., Foss, Francine M, Pinter-Brown, Lauren C., Carson, Kenneth R., Rosen, Steven T., Pro, Barbara, Hsi, Eric D., Federico, Massimo, Gisselbrecht, Christian, Schwartz, Marc, Bellm, Lisa A, Acosta, Mark, Advani, Ranjana H., Feldman, Tatyana A, Lechowicz, Mary Jo, Smith, Sonali M., Lansigan, Frederick, Tulpule, Anil, Craig, Michael, Greer, John P., Kahl, Brad S, Leach, Joseph W, Morganstein, Neil, Casulo, Carla, and Shustov, Andrei R.

Published
2017
Full Text
View/download PDF

129. Adjusting Starting Points for Initial Price Offers: The Example of Ibrutinib.

Author

Gibbons, Jason B., Bennett, Charles L., Carson, Kenneth R., and Anderson, Gerard F.

Subjects
*CHRONIC lymphocytic leukemia, *ANTINEOPLASTIC agents, *NEGOTIATION, *MEDICARE, *ECONOMICS, *PHARMACEUTICAL industry, *PATENTS, *MEDICAL care costs
Abstract

The Inflation Reduction Act of 2022 (IRA) allows the Medicare program to negotiate drug prices beginning in 2024. Based on the guidance in the statute, CMS has selected specific data items to use to adjust initial price offers for 10 drugs in the decision-making process. Although much of the data are publicly available, some of these data items will need to be collected directly from drug companies. A 2019 US House of Representatives Committee on Oversight and Accountability investigative report collected a wide range of data from manufacturers of 12 high-revenue drugs that show what is available from the drug companies, including development costs, marketing, pricing, competition, and patent status. This article focuses on the data obtained for ibrutinib, an oral medication for treating hematologic malignancies, which is one of the only drugs reviewed by the committee that also has been selected for Medicare price negotiation. We examine data that can be obtained only from the drug manufacturer that the IRA has explicitly identified as being used to determine the price and suggest potential negotiation strategies for CMS in response. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

130. Obesity and the Transformation of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma: A Population-Based Cohort Study.

Author

Su-Hsin Chang, Suhong Luo, Thomas, Theodore S., O'Brian, Katiuscia K., Colditz, Graham A., Carlsson, Nils P., Carson, Kenneth R., Chang, Su-Hsin, and Luo, Suhong

Subjects
MONOCLONAL gammopathies, MULTIPLE myeloma treatment, DISEASE progression, OBESITY treatment, CLINICAL trials, WEIGHT loss, STATISTICS on Black people, BODY weight, LONGITUDINAL method, MULTIPLE myeloma, OBESITY, WHITE people, COMORBIDITY, BODY mass index, RETROSPECTIVE studies
Abstract

Background: Multiple myeloma (MM) is one of the most common hematologic malignancies in the United States and is consistently preceded by monoclonal gammopathy of undetermined significance (MGUS). This study investigates the role of obesity in the progression of MGUS to MM.Methods: A retrospective identified cohort of patients in the US Veterans Health Administration database diagnosed with MGUS between October 1, 1999, and December 31, 2009, was followed through August 6, 2013. Patient-level clinical data were reviewed to verify MM diagnosis, if any. Survival analyses utilizing interval-censored data were used to investigate the risk of progression of MGUS to MM. Statistical tests were two-sided.Results: The analytic cohort consisted of 7878 MGUS patients with a median follow-up of 68 months. Within the cohort, 39.8% were overweight and 33.8% were obese; 64.1% were of white race. During follow-up, 329 MGUS patients (4.2%) progressed to MM: 72 (3.5%) normal-weight patients (median follow-up = 61.9 months), 144 (4.6%) overweight patients (median follow-up = 69.1 months), and 113 (4.3%) obese patients (median follow-up = 70.6 months). In the multivariable analysis, overweight (hazard ratio [HR] = 1.55, 95% confidence interval [CI] = 1.16 to 2.06) and obesity (HR = 1.98, 95% CI = 1.47 to 2.68) were associated with an increased risk of transformation of MGUS to MM. Moreover, black race was associated with a higher risk of MM (HR = 1.98, 95% CI = 1.55 to 2.54).Conclusions: Obesity and black race are risk factors for transformation of MGUS to MM. Future clinical trials should examine whether weight loss is a way to prevent the progression to MM in MGUS patients. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

131. A prospective cohort study of patients with peripheral T-cell lymphoma in the United States.

Author

Carson, Kenneth R., Horwitz, Steven M., Pinter‐Brown, Lauren C., Rosen, Steven T., Pro, Barbara, Hsi, Eric D., Federico, Massimo, Gisselbrecht, Christian, Schwartz, Marc, Bellm, Lisa A., Acosta, Mark A., Shustov, Andrei R., Advani, Ranjana H., Feldman, Tatyana A., Lechowicz, Mary Jo, Smith, Sonali M., Lansigan, Frederick, Tulpule, Anil, Craig, Michael D., and Greer, John P.

Subjects
*T-cell lymphoma, *LYMPHOMAS, *CUTANEOUS T-cell lymphoma, *HEMATOLOGIC malignancies, *LYMPHATIC diseases
Abstract

Background: Long-term survival in patients with aggressive peripheral T-cell lymphoma (PTCL) is generally poor, and there currently is no clear consensus regarding the initial therapy used for these diseases. Herein, the authors analyzed treatment patterns and outcomes in a prospectively collected cohort of patients with a new diagnosis of nodal PTCL in the United States.Methods: Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment (COMPLETE) is a prospective multicenter cohort study designed to identify the most common prevailing treatment patterns used for patients newly diagnosed with PTCL in the United States. Patients with nodal PTCL and completed records regarding baseline characteristics and initial therapy were included in this analysis. All statistical tests were 2-sided.Results: Of a total of 499 patients enrolled, 256 (51.3%) had nodal PTCL and completed treatment records. As initial therapy, patients received doxorubicin-containing regimens (41.8%), regimens containing doxorubicin plus etoposide (20.9%), other etoposide regimens (15.8%), other single-agent or combination regimens (19.2%), and gemcitabine-containing regimens (2.1%). Survival was found to be statistically significantly longer for patients who received doxorubicin (log-rank P = .03). After controlling for disease histology and International Prognostic Index, results demonstrated a trend toward significance in mortality reduction in patients who received doxorubicin compared with those who did not (hazard ratio, 0.71; 95% confidence interval, 0.48-1.05 [P = .09]).Conclusions: To the authors' knowledge, there is no clear standard of care in the treatment of patients with PTCL in the United States. Although efforts to improve frontline treatments are necessary, anthracyclines remain an important component of initial therapy for curative intent. Cancer 2017;123:1174-1183. © 2016 American Cancer Society. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

132. Weight change trends and overall survival in United States veterans with follicular lymphoma treated with chemotherapy.

Author

Xiao, Daphne Y., Luo, Suhong, O'Brian, Katiuscia, Liu, Weijian, and Carson, Kenneth R.

Subjects
PHYSIOLOGICAL aspects of body weight, LYMPHOMAS, LYMPHOMA treatment, SURVIVALISM, SURVIVAL behavior (Humans), PROGNOSIS
Abstract

Understanding weight change patterns in follicular lymphoma (FL) may be important for the assessment of prognosis as well as the long-term care of survivors. A retrospective cohort of United States veterans with a new diagnosis of FL between October 1, 1998 and September 30, 2010 was assembled. Weight changes were evaluated before, during, and after treatment in 896 FL patients who received cyclophosphamide, doxorubicin, vincristine, and prednisone, with or without rituximab (CHOP ± R); cyclophosphamide, vincristine, and prednisone, with or without rituximab (CVP ± R); or rituximab monotherapy. Weight decreased an average of 1.4 kg during therapy, and >5% weight loss during this time period was associated with worse overall survival. Weight increased to an average of 1.4 kg above baseline by 24 months after treatment initiation, with 15% gaining greater than 10% of their baseline weight. Weight management strategies may be an important part of long-term survivorship planning. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

135. Patient Characteristics and Initial Treatment Patterns in the United States for the Most Common Subtypes of Peripheral T-Cell Lymphoma (PTCL)

Author

Pinter-Brown, Lauren, primary, Foss, Francine M., additional, Carson, Kenneth R., additional, Horwitz, Steven M., additional, Rosen, Steven T., additional, Pro, Barbara, additional, Federico, Massimo, additional, Gisselbrecht, Christian, additional, Hsi, Eric D., additional, Shustov, Andrei R., additional, Advani, Ranjana, additional, Feldman, Tatyana, additional, Lechowicz, Mary Jo, additional, Smith, Sonali, additional, Tulpule, Anil, additional, Greer, John P., additional, Kahl, Brad S., additional, Leach, Joseph, additional, Morganstein, Neil, additional, Casulo, Carla, additional, and Park, Steven I., additional

Published
2014
Full Text
View/download PDF

139. Five hematologic tests and treatments to question

Author

Hicks, Lisa K., primary, Bering, Harriet, additional, Carson, Kenneth R., additional, Haynes, Adam E., additional, Kleinerman, Judith, additional, Kukreti, Vishal, additional, Ma, Alice, additional, Mueller, Brigitta U., additional, O'Brien, Sarah H., additional, Panepinto, Julie A., additional, Pasquini, Marcelo C., additional, Rajasekhar, Anita, additional, Sarode, Ravi, additional, and Wood, William A., additional

Published
2014
Full Text
View/download PDF

142. The ASH Choosing Wisely® campaign: five hematologic tests and treatments to question

Author

Hicks, Lisa K., primary, Bering, Harriet, additional, Carson, Kenneth R., additional, Kleinerman, Judith, additional, Kukreti, Vishal, additional, Ma, Alice, additional, Mueller, Brigitta U., additional, O'Brien, Sarah H., additional, Pasquini, Marcelo, additional, Sarode, Ravindra, additional, Solberg, Lawrence, additional, Haynes, Adam E., additional, and Crowther, Mark A., additional

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results